Podcasts about Commercialization

Silicon solar panels have led the market for decades but will soon hit a ceiling around 25% efficiency. Perovskite, a frontier material once dismissed for degrading too fast, is now being called the holy grail of solar. Saritha Peruri, VP of Commercialization at Tandem PV, is bringing it to market. The company stacks its proprietary perovskite on top of silicon, capturing a wider spectrum of light and pushing efficiency past 30%, a major jump over conventional solar. And because it builds on the silicon PV infrastructure that already exists, the path to scale stays simple. Getting there wasn't easy. After a long Series A, Tandem PV pulled off something rare in deep-tech hardware: 100% equipment financing for its 40-megawatt demonstration factory. It's now shipping quarter-sized modules to utility-scale customers who want U.S.-made panels for supply chain certainty and the domestic content kicker. It's potentially a bridge to a post-ITC world that cuts land and labor costs because each installation needs far fewer modules. In this episode, host Lara Pierpoint talks with Saritha about reaching high durability and the challenges of financing deep-tech hardware. Credits: Hosted by Lara Pierpoint. Produced and edited by Ross Kenyon and Anne Bailey. Technical direction by Sean Marquand. Stephen Lacey is our executive editor. The Green Blueprint is a co-production of Latitude Media and Trellis Climate. Subscribe on Apple, Spotify, or anywhere you get podcasts. For more reporting on the companies featured in this show, subscribe to Latitude Media's newsletter.

  Click Play Above to Hear Our Entire Podcast - Or Right Click and Save to Your Device and Listen Later SEGMENT ONE GUEST: Rick B. Nef, Commercialization

This week on Autonomy Signals presented by KPMG Grayson Brulte and Rob Grant discuss Figure AI's first commercial humanoid deployment with Catalyst Brands, Stellantis L2++ partnership with Wayve, and Starship Technologies surpassing 10 million autonomous deliveries.Figure AI recently signed a commercial agreement with Catalyst Brands to deploy humanoid robots at a JCPenney distribution center in Reno, Nevada, integrating Figure's humanoids into Catalyst's Joey Pouch sorting system.As new management at Stellantis looks to turn around the global OEM, the company is pursuing a partnership over build strategy to accelerate their expansion into the L2++ market, with a targeted launch beginning with the Jeep Grand Cherokee.Then there is Starship Technologies, which recently surpassed 10 million autonomous deliveries with 3,000 robots operating across more than 300 locations in eight countries. The company says autonomous delivery is already $3 to $4 cheaper than rider-based models, with a long-term target of $1 per drop, though sustained profitability will require lowering the teleoperator intervention rate to near zero while navigating city-by-city municipal regulation.Episode Chapters00:00 Signal 1: Figure AI Signs Commercial Agreement with Catalyst Brands18:10 Signal 2: Stellantis Partners with Wayve to Deploy L2++ in U.S.41:06 Signal 3: Starship Technologies Surpasses 10 Million Autonomous Deliveries59:13 AUTNMY AIAutonomy Signals is presented by KPMG.--------About The Road to AutonomyThe Road to Autonomy is the leading applied intelligence platform covering the convergence of automation, autonomy, and the Autonomy Economy.™.Through our podcasts, newsletter, and proprietary market intelligence, we set the narrative for institutional investors, industry executives, and policymakers navigating the convergence of automation, autonomy, and economic growth.Join institutional investors and industry leaders who read This Week in The Autonomy Economy every Sunday. Each edition delivers exclusive insight and commentary on the autonomy economy, helping you stay ahead of what's next.Subscribe today: https://www.roadtoautonomy.com/ae/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What actually creates innovation? Is it technology, intelligence, funding… or something much deeper? In this episode of Success Leaves Clues, Robin Bailey and Al McDonald sit down with Hugh Chow, CEO at ventureLAB, inventor, entrepreneur, investor, and global innovation leader, to explore the mindset behind breakthrough leadership, meaningful innovation, and building companies that create lasting impact.With more than 30 years of experience across semiconductors, startups, venture capital, sustainability, and global technology, Hugh shares the deeply personal journey that shaped his perspective on leadership, opportunity, and resilience. From immigrating to North America to helping scale technology companies with hundreds of patents and hundreds of millions in revenue, Hugh unpacks what it really takes to build something meaningful in a rapidly changing world.This conversation explores the future of Canadian innovation, why founders need to think globally from day one, and how true innovation comes from challenging the status quo rather than accepting it. Hugh also shares why he believes leadership is about creating opportunities for others, lifting people up, and planting seeds for future generations to grow.Throughout the episode, Hugh offers powerful insights on entrepreneurship, commercialization, AI, hardtech, startup ecosystems, mentorship, and the lessons he learned from his parents that continue to guide his leadership today.If you've ever wondered what separates visionary leaders from everyone else, or how innovation can become a force for long-term impact, this episode delivers a masterclass in leadership, humility, and purpose-driven growth.You'll hear about:Why innovation starts with challenging the status quo The leadership philosophy behind building win-win relationships How one phone call changed the trajectory of Hugh's career Why great leaders recognize talent before people see it in themselves The difference between taking risks and creating opportunity Why Canadian founders need to think globally from the beginning The commercialization gap holding Canadian innovation back What makes Canada one of the strongest innovation ecosystems in the world The future of AI, hardtech, and medical technology startups Why learning matters more than avoiding failure The importance of sustainability and lifting others up How Hugh's parents shaped his approach to leadership and resilienceWe talk about:00:00 Introduction to Hugh Chow and ventureLAB02:00 Seeing potential in people before they see it themselves05:00 Why leadership is about creating win-win opportunities08:30 The career moments that shaped Hugh's innovation mindset10:00 Moving to North America and starting in semiconductors13:00 Building a global technology company from Canada15:00 What innovation actually means in today's world17:00 Why innovation requires challenging the status quo19:00 Leadership, sustainability, and creating long-term impact21:00 Canada's strengths in innovation and AI23:00 Why Canadian companies must think globally25:00 Commercialization challenges in Canada28:00 The future of hardtech, AI, and medical technology31:00 What founders often misunderstand about success34:00 Supporting startups through uncertainty and change36:00 The question every leader should ask themselves38:00 Hugh's parents, resilience, and the lessons that shaped his life42:00 Why opportunity should be passed on to future generationsConnect with HughLinkedIn: https://www.linkedin.com/in/hugh-chow-445b332/ Website: https://www.venturelab.ca/ Connect with UsLinkedIn: Robin Bailey and Al McDonald Website: Aria Benefits and Life & Legacy Advisory Group

Stephen Grootes speaks to Francois Rossouw, CEO of Southern African Agri Initiative, about the Pretoria High Court’s landmark ruling allowing farmers and livestock owners to privately procure and administer Foot-and-Mouth Disease vaccines without State veterinary involvement In other interviews, Kelvin Watt, Chairman of Nielsen Sports Africa talks about the battle for South African sports audiences between soccer and rugby, and which codes are attracting the biggest commercial opportunities, the growing sponsorship value and what South Africans’ deep emotional connection to sport reveals about consumer behaviour, brand loyalty and the future of sports entertainment. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Moore's Law has been a cornerstone of the rapid advancement of digital technology over the past decades, although it is now confronting physical limits and diminishing economic returns.过去几十年，摩尔定律一直是数字技术快速进步的基石，尽管如今它正面临物理极限和边际收益递减的挑战。For an industry conditioned to equate progress with nanometers, the Tau Scaling Law disclosed by Huawei on Monday is a challenge to the organizing logic of the semiconductor ecosystem.对于一个习惯于用纳米衡量进步的行业而言，华为5月25日公布的“τ scaling law”（陶缩放定律）无疑是对半导体生态系统运行逻辑的一次挑战。Instead of continuing the increasingly expensive race to shrink transistors, Tau Scaling proposes that future chip performance gains can come from compressing the signal propagation time through architectural and timing innovations. Huawei has set a target of reaching a chip density equivalent to 1.4 nanometers by 2031.陶缩放定律提出，摒弃代价日益高昂的晶体管微缩竞赛，转而通过架构与时序创新压缩信号传播时间，驱动未来芯片性能提升。华为已设定目标，到2031年实现相当于1.4纳米制程的芯片密度。Washington's export restrictions have attempted to cut China off from advanced lithography equipment, leading-edge foundries and portions of the global event-driven architecture software stack. Such measures were designed to slow China's progress in advanced semiconductors.美国的出口限制试图将中国排除在先进光刻设备、前沿代工厂以及部分全球事件驱动架构软件栈之外。这些措施旨在减缓中国在先进半导体领域的进步。That is where Tau Scaling enters the picture. Instead of shrinking transistor dimensions from 3 nm to 2 nm and beyond, Huawei is extracting more performance from mature process nodes such as 5 nm and 7 nm by means of architectural optimization, timing compression, logic folding and system-level coordination.这正是陶缩放定律发挥作用的地方。华为不再追求从3纳米到2纳米及更小尺寸的晶体管微缩，而是通过架构优化、时序压缩、逻辑折叠和系统级协调等手段，从5纳米、7纳米等成熟工艺节点中挖掘更多性能。Much of the underlying research — including asynchronous computing concepts, wave pipelining, and timing optimization techniques — can be traced back decades. What Huawei has done, under conditions where the traditional scaling route became inaccessible, is to revisit those ideas, combine them, enhance them and industrialize them.许多基础性研究，包括异步计算概念、波流水线技术和时序优化技术等都可以追溯到几十年前。华为所做的，是在传统微缩路径受阻的情况下，重新审视这些想法，将它们加以融合、改进并产业化。In that sense, the emergence of Tau Scaling reflects a broader historical pattern in technology. Constraints often redirect innovation rather than stop it. So, if chip performance can be improved through architecture rather than lithography alone, then the balance of competition changes. The key question becomes not simply who owns the most advanced EUV machines, but who can design the most efficient systems using available manufacturing capabilities.从这个意义上说，陶缩放定律揭示了技术发展的一条普遍规律：限制往往促使创新转向，而非将其扼杀。若芯片性能可借架构而非单纯依赖光刻技术提升，竞争的格局便将随之改变。关键问题不再是“谁拥有最先进的极紫外光刻机”，而是“谁能利用现有制造能力设计出最高效的系统”。It would be premature, though, to declare that the arrival of Tau Scaling heralds the post-Moore era. Semiconductor history is filled with elegant concepts that struggled once they encountered manufacturing economics, ecosystem inertia, or commercial realities. Huawei's proposal faces several important ceilings.不过，现在就说陶缩放定律预示后摩尔时代已经开启，未免为时过早。半导体发展史上不乏精妙构想，但一旦遭遇制造经济学、生态系统惯性或商业现实，便会步履维艰。华为的方案目前仍面临若干关键瓶颈。Architecture cannot completely replace physics. Timing optimization can reduce inefficiencies, but signals still obey physical propagation limits. As chips become larger and workloads more complex, interconnect delays and synchronization overhead remain major bottlenecks.架构终究无法替代物理规律。时序优化虽能减少低效，信号却始终受制于物理传播的极限。随着芯片尺寸不断增大、工作负载日趋复杂，互连延迟与同步开销仍是绕不开的主要瓶颈。Logic folding and time-domain optimization introduce their own complexity penalties. The more aggressively a design compresses timing, the harder verification, debugging and manufacturing become. Commercialization will determine whether Tau Scaling becomes an industry framework. For Huawei's approach to become influential, other companies must adopt it, customers must validate it and developers must build around it. That process will take years, not conference announcements.逻辑折叠与时域优化本身也需付出复杂性代价。设计越激进地压缩时序，验证、调试与制造的难度便越大。陶缩放定律能否成为行业框架，最终取决于商业化落地。华为的方案要产生影响力，必须获得其他公司的采纳、客户的验证以及开发者的生态共建。这需要数年之功，而非一场发布会所能成就。Even so, the broader lesson already stands. The semiconductor industry is entering a phase where innovation no longer relies exclusively on brute-force scaling and trillion-dollar capital expenditures. Architectural intelligence, software-hardware codesign, advanced packaging and system optimization are becoming increasingly important.即便如此，一个更宏观的启示已然显现：半导体行业正步入新阶段——创新不再单纯依赖蛮力微缩与万亿美元级的资本投入。架构智能、软硬件协同设计、先进封装与系统优化，正变得日益关键。For China, that shift creates both an opportunity and a responsibility. The country still faces major gaps in lithography, materials, EDA tools and manufacturing equipment. But Tau Scaling demonstrates something equally important: when external pressure blocks one route, researchers will look for alternative routes and solutions can emerge through persistence, engineering discipline and targeted input.对中国而言，这一转变既是机遇，也是责任。尽管在光刻、材料、EDA工具及制造设备上差距显著，但陶缩放定律揭示了一个重要道理：外部压力堵住一条路，科研人员就会开辟另一条路。凭借坚韧、工程严谨和精准投入，解决方案终将破土而出。The semiconductor race is no longer just about making things smaller. Increasingly, it is about making systems smarter. The challenge now is for more Chinese companies and engineers to push beyond incremental imitation and focus on resolving genuine choke-point technologies with the tools they already possess.半导体竞赛，已从单纯追求“更小”转向致力实现“更智能”。当务之急，是更多中国企业与工程师超越渐进式模仿，立足现有工具，攻克真正的“卡脖子”技术。Moore's Law /mʊəz lɔː/摩尔定律diminishing economic returns /dɪˈmɪnɪʃɪŋ ˌiːkəˈnɒmɪk rɪˈtɜːnz/边际收益递减conditioned to /kənˈdɪʃənd tuː/习惯于Tau Scaling Law /taʊ ˈskeɪlɪŋ lɔː/ τ缩放定律（陶缩放定律）semiconductor ecosystem /ˌsemikənˈdʌktər ˈiːkəʊsɪstəm/半导体生态系统shrink transistors /ʃrɪŋk trænˈzɪstəz/微缩晶体管advanced lithography equipment /ədˈvɑːnst lɪˈθɒɡrəfi ɪˈkwɪpmənt/先进光刻设备leading-edge foundries /ˈliːdɪŋ edʒ ˈfaʊndriz/前沿代工厂event-driven architecture /ɪˈvent ˈdrɪvən ˈɑːkɪtektʃə/事件驱动架构asynchronous computing /eɪˈsɪŋkrənəs kəmˈpjuːtɪŋ/异步计算wave pipelining /weɪv ˈpaɪplaɪnɪŋ/波流水线EUV machines /ˌiː juː ˈviː məˈʃiːnz/极紫外光刻机post-Moore era /pəʊst mʊə ˈɪərə/后摩尔时代manufacturing economics /ˌmænjʊˈfæktʃərɪŋ ˌiːkəˈnɒmɪks/制造经济学ecosystem inertia /ˈiːkəʊsɪstəm ɪˈnɜːʃə/生态系统惯性software-hardware codesign /ˈsɒftweə ˈhɑːdweə ˌkəʊdɪˈzaɪn/软硬件协同设计advanced packaging /ədˈvɑːnst ˈpækɪdʒɪŋ/先进封装system optimization /ˈsɪstəm ˌɒptɪmaɪˈzeɪʃən/系统优化lithography /lɪˈθɒɡrəfi/光刻EDA tools /ˌiː diː ˈeɪ tuːlz/电子设计自动化工具

Stephen Grootes speaks to Kelvin Watt, chairperson of Nielsen Sports Africa, about the battle for South African sports audiences between soccer and rugby, and which codes are attracting the biggest commercial opportunities. They also look at the growing sponsorship value and what South Africans’ deep emotional connection to sport reveals about consumer behaviour, brand loyalty and the future of sports entertainment. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Stay informed on current events, visit www.NaturalNews.com  - Memorial Day Message and Introduction to Energy Technology (0:02) - Impact of the War in Iran on Energy Technology (3:59) - Commercialization and Future of LENR Technology (8:00) - Challenges and Opportunities in Energy Transition (9:11) - Memorial Day Sale and Store Updates (9:34) - Translation Projects and Future Plans (12:26) - Impact of the War in Iran on Global Energy Supply (14:56) - Advancements in Battery Technology (36:37) - Challenges in Data Center Development (56:16) - Potential for Decentralized Power Production (1:17:59) - X AI's Tactics and Community Pushback (1:18:16) - Health Impact of Gas Turbines (1:20:33) - Community Action and Activist Movements (1:22:41) - Technological Overkill and Data Center Viability (1:29:53) - China's Role in Data Center Scaling (1:33:58) - Digital ID and Surveillance Infrastructure (1:37:57) - The Spiritual and Practical Implications of Data Centers (1:46:01) - The Role of Decentralized Technology (1:53:12) - The Impact of Social Media and Addictions (2:06:28) - The Importance of Natural Dopamine Support (2:11:30) - Impact of Media and Pharma on Public Perception (2:33:51) - Awareness and Establishment Resistance (2:36:03) - Historical and Current Pharma Scandals (2:39:20) - Natural Solutions and Superfoods (2:41:33) - Impact of Toxic Ingredients and Seed Oils (2:45:28) - Glyphosate and Corporate Influence (2:53:25) - Personal Responsibility and Health Awareness (2:57:10) - Addiction Rescue Course and Dopamine Revolution (3:00:05) - Memorial Day Sale and Health Ranger Store (3:03:35) - Final Thoughts and Encouragement (3:08:55) Watch more independent videos at http://www.brighteon.com/channel/hrreport  ▶️ Support our mission by shopping at the Health Ranger Store - https://www.healthrangerstore.com ▶️ Check out exclusive deals and special offers at https://rangerdeals.com ▶️ Sign up for our newsletter to stay informed: https://www.naturalnews.com/Readerregistration.html Watch more exclusive videos here:

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adapting to regulatory inconsistencies around rare disease drug approval frameworks in the U.S. and Europe.     Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode of BioTalk with Rich Bendis, Sam Gussman-Toh, Portfolio Manager for the Small Business Program at ARPA-H, joins the conversation to discuss how the agency is creating new pathways for small businesses developing ambitious health technologies. Sam explains how the ARPA-H model differs from traditional federal funding programs, with a focus on moonshot health solutions, program manager-led portfolios, milestone-driven contracts, and a strong emphasis on moving technologies toward real-world use. He also discusses how the Small Business Program supports SBIR and STTR performers through Phase I, Phase II, Direct to Phase II, and Fast Track awards. The conversation highlights how ARPA-H is working with ambitious small businesses, including non-traditional companies and early-stage startups that may be working with the federal government for the first time. Sam also shares how commercialization support is built into the program, including ARPA-H's Entrepreneur-in-Residence partnership with BioHealth Innovation. Through that relationship, BHI EIRs help performers strengthen regulatory strategy, intellectual property planning, go-to-market strategy, reimbursement considerations, and other key commercialization needs. Sam also discusses ARPA-H's draft Small Business Program solicitation, the upcoming virtual Proposers' Day on June 11, and what companies should know about the application process, topic areas, technical pitches, and future funding opportunities. Editing and post-production work for this episode was provided by The Podcast Consultant. Sam Gussman-Toh is Portfolio Manager for the Small Business Program at ARPA-H, where he coordinates and oversees the agency's SBIR/STTR awards and commercialization support services for participating small businesses. Sam joined ARPA-H in 2022 and wrote the agency's first SBIR/STTR solicitation. He has held several roles in the Office of Commercialization and has worked closely with Program Managers to build the agency's commercialization infrastructure and strategy. Previously, Sam designed and managed rapid prototyping programs across agencies in the Department of War. His technical background is in computer science, with interests in computer vision, autonomous robotic systems, and computational pathology.

Are we alone? In this short-isode, Elton traces the bizarre, hilarious, and occasionally unhinged history of humanity's quest for alien communication. From Frank Drake's Equation in 1961, a mathematical roadmap for the search for extraterrestrial intelligence (SETI), to the times before radio, when our ideas were pure fantasy: he dives into the wild ideas and scams. Like, the 19th-century scheme to burn massive geometric messages onto the surface of Mars using a gargantuan, laser-focused mirror. For real.From those ambitious, largely insane, early visual signals to the iconic messages we've strapped to spaceships—we've spent centuries leaving a very expensive voicemail for an unknown recipient.We also explore the cosmic artifacts and phenomena that made us stop and whisper, "Is someone calling us?" Learn the true story behind the Black Knight Satellite (spoiler: it's an escaped blanket), the enduring mystery of the Wow! Signal, and the strange case of 'Oumuamua, the cigar-shaped interstellar visitor.Finally, we confront the ultimate cosmic buzzkill: the Fermi Paradox. If the galaxy should be crowded, "Where is everybody?" We discuss the terrifying ethical debate over intentional messaging (METI) and the chilling logic of the Dark Forest Theory. Tune in to find out why, even in crushing silence, we simply cannot stop shouting "Hello?" into the dark.GET THE BOOK: ⁠⁠⁠⁠⁠From Amazon⁠⁠⁠⁠⁠⁠⁠⁠From an Indie Book Seller⁠⁠⁠⁠BECOME AN Elton Reads A Book A Week CONTRIBUTOR HERE:⁠⁠⁠⁠⁠⁠Elton Reads A Book A Week Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Buy Me A Coffee!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SOCIAL MEDIA!⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠This is the LINK TREE!⁠⁠⁠⁠⁠⁠⁠⁠Join the Discord server!⁠⁠⁠EMAIL: eltonreadsabookaweek@gmail.comThe following section is reserved for the people, places, things, and more that Elton probably offended in this episode--THE APOLOGIES SECTION: Martians, New Yorkers...again, TalkToAliens.com users, UFO conspiracy theorists, etc.A special thanks to Diedrich Bader and Jenna Fischer for all their inspiration.Tags: Drake Equation, Fermi Paradox, SETI, METI, Extraterrestrial Intelligence, Frank Drake, Cosmic Silence, Voyager Golden Records, Pioneer Plaques, Arecibo Message, Alien Communication, Interstellar Communication, Charles Cros, Wow! Signal, Black Knight Satellite, 'Oumuamua, Dark Forest Theory, UFO, Space Mystery, Long Delayed Echoes (LDEs), Baltic, Martian Lasers, Nikola Tesla, Cosmic Chat, Alien Conspiracies, Commercialization of Space, Space Hoaxes, Science Podcast, Short-isode, Elton Reads a Book a Week, Books and Reading, Infotainment, learning, fun, comedy, history

We're in London at the INTA 2026 Annual Meeting, but we're not doing a standard conference recap. We wanted to show how intellectual property work can be creative, inventive, and even fun, so we built THE INVENTIVE MINDSET GAME, a scenario game, and handed real IP lawyers a stack of tricky client prompts.Each prompt forces a choice: do you follow the client's exact instructions, take an inventive counseling path, bring in an AI assist tool, or throw a curveball and plan for the worst-case scenario. From a smart home invention to a viral character and an influencer launching a skincare line, we dig into the practical decisions behind patent strategy, trademark protection, and copyright, including how to think about prior art, claim scope, brand control, and what “commercialization” actually demands.We also talk about the unglamorous but critical details that can make or break an IP strategy: picking the right trademark classes, avoiding coverage that doesn't match the business, and sequencing filings when budgets are tight. If you're a founder, creator, in-house counsel, or just curious about how IP law works in the real world, you'll leave with clearer mental models and sharper questions to ask before you file anything.Subscribe for more stories and practical IP insights, share this with a friend building a brand, and leave a review if the game format helped you think differently about IP. What would you choose first: safe, inventive, AI-assisted, or curveball?Send us Fan MailCheck out "Protection for the Inventive Mind" – available now on Amazon in print and Kindle formats.The views and opinions expressed (by the host and guest(s)) in this podcast are strictly their own and do not necessarily reflect the official policy or position of the entities with which they may be affiliated. This podcast should in no way be construed as promoting or criticizing any particular government policy, institutional position, private interest or commercial entity. Any content provided is for informational and educational purposes only.

Commercialization decisions are shaping success earlier than ever in the product lifecycle, from value and access to launch strategy, deployment and stakeholder engagement. Conversations on Commercialization, a new spinoff of the Syneos Health Podcast, explores what this shift means for biopharma companies and what it takes to compete in a rapidly evolving market. Led by Tyler Cowan, Commercial Vice President at Syneos Health, and joined by a bench of expert co-hosts, the podcast brings together industry leaders to explore the trends, decisions and evolving commercial models defining success today.Subscribe to The Syneos Health Podcast: Conversations on Commercialization so you never miss an episode. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us!  We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

In this episode, Richard Clapp, retired principal consultant from DuPont, joins co-hosts Heather Allain and Marc Cook for a discussion on the role of materials expertise in process commercialization. Drawing on decades of industry experience, Richard outlines the three primary types of process commercialization and the institutional challenges companies often face when scaling new processes from the bench to production. The conversation explores how impurities, feedstock variability, and solids handling can introduce unexpected complications, as well as why engineers tend to take conservative approaches to materials recommendations during commercialization efforts. Richard also breaks down common “show stoppers” and explains the importance of the three C's—corrosion, compatibility, and clean-up—when evaluating process systems. Additional topics include corrosion testing at both bench and pilot scale, the subtle but important differences that can exist between seemingly identical plants, considerations when using toll manufacturers for pilot operations, and practical advice for organizations navigating process commercialization projects.   This episode is sponsored by Tricor Metals and Rolled Alloys.   Corrosion Chronicles is produced by Association Briefings.

Welcome to episode #1034 of Thinking With Mitch Joel (formerly Six Pixels of Separation). At a time when the lines between culture, commerce and identity feel increasingly blurred, few people understand how value is actually constructed… and reconstructed… better than Douglas Woodham. A former President of the Americas at Christie's and a longtime advisor through his firm Art Fiduciary Advisors, Doug brings a rare dual lens to the conversation… equal parts economist and art obsessive. With a PhD in economics and decades spent inside the machinery of the global art market, he has seen firsthand how artists move from obscurity to icon status… and how markets, narratives and power structures shape that journey . His latest book, Jean-Michel Basquiat - The Making of an Icon, goes far beyond biography to examine how one artist's legacy was not just created… but carefully engineered. In this conversation, Doug explores the intersection of art and economics, unpacking how scarcity, status and human behavior drive the desire to collect… and why ownership has become increasingly performative in a social media age. He challenges the romantic notion that value is purely about the work itself, pointing instead to branding, cultural timing and strategic stewardship… particularly in Basquiat's posthumous rise. We also dig into the broader shifts reshaping the art world… from the declining cultural centrality of fine art to the rise of alternative collectibles, the failure of NFTs to gain traction in traditional markets, and the fragile economics behind fractional ownership models. What emerges is a sharper understanding that art is not just about beauty or expression… it is about markets, narratives and belief systems that determine what is worth owning… and why. Enjoy the conversation… Running time: 1:04:35. Hello from beautiful Montreal. Listen and subscribe over at Apple Podcasts. Listen and subscribe over at Spotify. Please visit and leave comments on the blog - Thinking With Mitch Joel. Feel free to connect to me directly on LinkedIn. Check out ThinkersOne. Here is my conversation with Douglas Woodham. Jean-Michel Basquiat - The Making of an Icon. Art Fiduciary Advisors. Art Collecting Today. Follow Doug on Instagram. Follow Doug on LinkedIn. Chapters: (00:00) - Introduction to Doug Woodham and His Expertise. (02:42) - The Life and Legacy of Jean-Michel Basquiat. (04:48) - Connecting Art and Economics. (08:45) - Human Behavior and the Desire for Collectibles. (12:10) - The Shift in Art Collecting Trends. (15:42) - NFTs and Their Impact on the Art Market. (20:29) - Artist Compensation and Ownership Rights. (24:28) - Cultural Relevance of Fine Art Today. (27:58) - The Psychology of Collecting and Scarcity. (32:37) - The Business of Scarcity in Consumer Brands. (35:15) - The Importance of Secondary Markets in Collectibles. (40:10) - The Evolution of Basquiat's Brand Posthumously. (54:51) - The Intersection of Art and Commercialization. (59:53) - Fractional Ownership in Art Investments.

In this episode, Nancy Young, VP of Commercialization at Cencora and Juliet Roldan, Associate Director of Radiology Operations at American Oncology Network give us a rundown on operationalizing radiopharmaceuticals in your practice.That is a wrap on our radiopharmaceutical series and we are excited for you to hear our upcoming episodes on legislation and bispecifics. If you have any other questions for our guests, or suggestions for future topics, email us at OnCall@cencora.com.Disclaimer: The OnCall podcast is for educational purposes only and not a substitute for any professional medical advice, legal advice, or clinical judgment. Views expressed are opinions only and not endorsed by Cencora or any of its affiliates. The opinions expressed are solely those of the author and may include certain marketing statements. The content of this presentation is owned or licensed by Cencora, and reproduction of the content is not permitted without Cencora's consent. Neither OnCall nor Cencora control the accuracy of any third-party information. Accessing any referenced site is subject to such site's terms of use.

The following article of the Health industry is: 'The AI Transformation of Pharmaceutical Commercialization' by Enrique Remezal, CEO, icon Group/Avanzia Pharma.

Humans have been exchanging tokens of friendship since before recorded history. From calling cards to Valentines to Christmas cards, the modern greeting card industry evolved. Research: “America’s First Christmas Card.” Albany Institute of History and Art. https://www.albanyinstitute.org/online-exhibition/50-objects/section/america-s-first-christmas-card Britannica Editors. "scarab". Encyclopedia Britannica, 3 Apr. 2014, https://www.britannica.com/topic/scarab Britannica Editors. "greeting card". Encyclopedia Britannica, 15 Mar. 2024, https://www.britannica.com/topic/greeting-card Brown, Ellen F. “Christmas, Inc.: A Brief History of the Holiday Card.” JSTOR Daily. Dec. 20, 2015. https://daily.jstor.org/history-christmas-card-holiday-card/ Chase, Ernest Dudley. “The Romance of Greeting Cards.” Rust Craft. Cambridge, MA. 1956. “Dali at Hallmark.” Hallmark Art Collection. https://www.hallmarkartcollection.com/creatively-thinking/stories/dali-at-hallmark/ “Esther Howland 1847.” Mount Holyoke. https://www.mtholyoke.edu/directory/alum/esther-howland Evans, Elaine Altman. “The Sacred Scarab, Occasional Paper.” McClung Museum of Natural History and Culture. University of Tennessee. January 1, 1996. https://mcclungmuseum.utk.edu/1996/01/01/sacred-scarab/ Greeting Card Association. “The History of Greeting Cards.” https://www.greetingcard.org/history/ Hanc, John. “The History of the Christmas Card.” Smithsonian. Dec. 9, 2015. https://www.smithsonianmag.com/history/history-christmas-card-180957487/ Henry, William E. “Art and Cultural Symbolism: A Psychological Study of Greeting Cards.” The Journal of Aesthetics and Art Criticism, vol. 6, no. 1, 1947, pp. 36–44. JSTOR, https://doi.org/10.2307/426176 Kavanagh, Marybeth. “Louis Prang, Father of the American Christmas Card.” The New York Historical. Dec. 19, 2012. https://www.nyhistory.org/blogs/prang Koon, Wee Kek. “How ancient Chinese new year cards went from elites’ greetings to bribery instruments.” South China Morning Post. Jan. 31, 2026. https://www.scmp.com/lifestyle/chinese-culture/article/3341675/how-ancient-chinese-new-year-cards-went-elites-greetings-bribery-instruments?module=perpetual_scroll_0&pgtype=article Korolkov, Maxim. “‘Greeting Tablets’ in Early China: Some Traits of the Communicative Etiquette of Officialdom in Light of Newly Excavated Inscriptions.” T’oung Pao, vol. 98, no. 4/5, 2012, pp. 295–348. JSTOR, http://www.jstor.org/stable/41725988 Lee, Ruth Webb. “A History of Valentines.” 1984. Newberry, Percy E. “Scarabs: An Introduction to the Study of Egyptian Seals and Signet Rings.” London. Archibald Constable and Co. Ltd. 1908. https://dn790001.ca.archive.org/0/items/scarabsintroduc00newbuoft/scarabsintroduc00newbuoft.pdf Purcell, Denise. “Authentic Messaging and Independent Makers Drive Greeting Cards' Next-Gen Relevance.” U.S. Chamber of Commerce. https://www.uschamber.com/co/good-company/launch-pad/greeting-card-next-gen-relevance#:~:text=The%20category%20is%20massive:%20According,card%20market%20at%20$7%20billion. Grafton, Samuel. “Holly Leaf and Copper Plate.” The North American Review, vol. 226, no. 6, 1928, pp. 660–64. JSTOR, http://www.jstor.org/stable/25110633 Shoichet, Catherine E. “This ‘visionary’ woman changed the way many Americans celebrate Valentine’s Day.” CNN. Feb. 14, 2024. https://edition.cnn.com/2024/02/13/style/esther-howland-valentines-card-history-cec Schmidt, Leigh Eric. “The Commercialization of the Calendar: American Holidays and the Culture of Consumption, 1870-1930.” The Journal of American History, vol. 78, no. 3, 1991, pp. 887–916. JSTOR, https://doi.org/10.2307/2078795 Stupperich, Andy. “Art Education: Louis Prang's Christmas Card Competitions.” The Henry Ford Museum. January 29, 2026. https://www.thehenryford.org/collections/explore/articles/art-education-louis-prang%27s-christmas-card-competitions Terrell, Ellen. “Esther Howland and the Business of Love.” Library of Congress. March 23, 2016. https://blogs.loc.gov/inside_adams/2016/03/esther-howland-and-the-business-of-love/ “World's first printed Valentine's Card.” A History of the World. BBC. 2014. https://www.bbc.co.uk/ahistoryoftheworld/objects/L1NM_6mWRymAMKXcRDlXJA Wright, Helena E. “A winning design: Prang’s Christmas card contests of the 1880s.” National Museum of American History. December 23, 2019. https://americanhistory.si.edu/explore/stories/winning-design-prangs-christmas-card-contests-1880s See omnystudio.com/listener for privacy information.

What if the innovation economy has always had a gender problem—and we just couldn't see it? Despite a wave of visibility for women entrepreneurs, the numbers are stark: 90% of inventors in Canada are male, and women-led ventures receive less than 5% of available funding. In this episode, UBC Sauder School of Business assistant professor Angèle Beausoleil (PhD'17)—a researcher, serial entrepreneur, and self-described "pracademic"—unpacks why innovation culture skews masculine, what groupthink costs organizations that ignore it, and why the traits society calls "feminine" might actually be the entrepreneurial superpowers we've been undervaluing all along.Links for this episodeTranscriptContact CarolContact JeevanFrom Here ForwardPodium Podcast CompanyContact Dr. Angele BeausoleilLearn more about Dr. Beausoleil's researchJeevan & Carol's Fave Canadian Businesses | Blume Skincare | Dexy Paws | Stranger Tails (00:00) - Introduction (01:56) - Meet Dr. Angele Beausoleil (04:24) - Is innovation “too masculine” & what does that mean? (06:51) - The numbers: inventors, founders, and venture funding (07:49) - The history: the “heroic innovator” and gendered norms (12:56) - The risk of ignoring bias (15:41) - Examples of women-led innovation (19:08) - How to begin to create change in innovation (21:44) - The Innovation Self-Assessment Study (26:48) - What needs to change (education, language, policies) (29:09) - Conclusion

Brian Webster, President and CEO of Kestra Medical Technologies (Nasdaq: KMTS), joins Medtech Talk to discuss his 30-year career in cardiac defibrillation and the road to founding Kestra. With host Swaril Mathur, Webster unpacks learnings from leading through decades of repeated acquisitions, divestitures, and restructurings — and keeping the team motivated through it all. Their conversation explores what it takes to commercialize a rental fleet model with outsourced manufacturing, revenue cycle management, and payer contracts, as well as closing with the decision to IPO and staying steady in volatile markets by focusing on execution fundamentals. Subscribe, share this with a MedTech operator who's scaling something hard, and leave a rating or review with the leadership lesson that hit you most. Medtech Talk Links:  Cambridge Healthtech Institute   Medtech Talk  Gilde Healthcare  MicroTransponderLinks: MicroTransponder Kestra Medical Technologies: Kestra Medical Technologies  

Has the true meaning of Christmas been lost in a sea of commercialization, distraction, and modern reinterpretation? In this thought-provoking episode, Robin Main explores Santa-Tizing and What's Wrong With Christmas—and How to Clean It Up, offering a critical look at how one of the world's most cherished holidays may have drifted from its original intent. Drawing from cultural observation and personal reflection, Robin discusses how traditions have evolved over time—sometimes shifting the focus away from deeper meaning and toward materialism and surface-level celebration. He examines the role of media, marketing, and societal habits in reshaping how Christmas is experienced today. This episode invites listeners to reconsider what the holiday represents. What elements of Christmas have been overshadowed or forgotten? How can individuals reconnect with a more meaningful, intentional celebration? And what steps can be taken to “clean up” the holiday in a way that restores its sense of purpose, connection, and authenticity? Join us for a compelling and reflective conversation that challenges convention and encourages a return to meaning—where the spirit of the season is rediscovered beyond the noise, and where tradition can be reimagined with clarity and intention.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-x-zone-radio-tv-show--1078348/support.Please note that all XZBN radio and/or television shows are Copyright © REL-MAR McConnell Meda Company, Niagara, Ontario, Canada – www.rel-mar.com. For more Episodes of this show and all shows produced, broadcasted and syndicated from REL-MAR McConell Media Company and The 'X' Zone Broadcast Network and the 'X' Zone TV Channell, visit www.xzbn.net. For programming, distribution, and syndication inquiries, email programming@xzbn.net.We are proud to announce the we have launched TWATNews.com, launched in August 2025.TWATNews.com is an independent online news platform dedicated to uncovering the truth about Donald Trump and his ongoing influence in politics, business, and society. Unlike mainstream outlets that often sanitize, soften, or ignore stories that challenge Trump and his allies, TWATNews digs deeper to deliver hard-hitting articles, investigative features, and sharp commentary that mainstream media won't touch.These are stories and articles that you will not read anywhere else.Our mission is simple: to expose corruption, lies, and authoritarian tendencies while giving voice to the perspectives and evidence that are often marginalized or buried by corporate-controlled media

In this episode of the Global Medical Device Podcast, host Etienne Nichols sits down with John Schindler, CEO of Liquet Medical, for a "MedTech Founder 101" masterclass. With over 25 years of experience at industry giants like Atrium and Merit Medical, Schindler shares the "painful reality checks" that come when transitioning from the structured umbrella of a large corporation to the high-stakes, resource-dependent world of a startup.The conversation dives deep into the philosophy of "novel but simple" technology. Schindler explains why simplicity is often harder to fund but essential for physician adoption and long-term market success. He challenges the current industry obsession with over-engineered solutions, arguing that the pendulum is swinging back toward intuitive, easy-to-use devices that don't "break the system" of healthcare delivery.Finally, the discussion covers the tactical realities of commercialization, including the nuances of the "Valley of Death." Schindler outlines why a limited market release is often superior to broad distribution and emphasizes the importance of building strategic enterprise value through intentional clinical data that speaks to both regulatory bodies and hospital value analysis committees.Key Timestamps00:45 – Introduction to John Schindler and Liquet Medical's mission.02:15 – The Corporate vs. Startup Reality: Losing the safety net of big-company resources.04:30 – Simplicity vs. Complexity: Why investors favor "shiny" tech but physicians crave simplicity.07:50 – The MedTech Innovator Experience: Leveraging human capital and "pressure testing" your company.10:15 – Unlearning Corporate Silos: The necessity of radical collaboration in early-stage teams.12:40 – Clinical Data Strategies: Moving beyond "clinical wins" to hospital value analysis.15:30 – Establishing "Soft Endpoints" for payers and rural healthcare settings.18:20 – Negotiating as a Cash-Strapped Startup: Approaching vendors and regulatory services with humility.21:10 – The Regulatory Chess Game: Why early engagement with the FDA prevents timeline resets.24:35 – Commercialization and the 510(k) vs. IDE strategy.27:15 – The Risks of Distribution Agreements: Why products "fall to the bottom of the bag."Quotes"The complexity can actually break the system in some ways. Physicians always gravitate back towards simplicity—things that are easy for them to wrap their heads around." - John SchindlerTakeawaysMaster the Holistic Approach: Founders should seek exposure to every facet of the business—sales, management, and business development—to understand how their innovation responds "in the trenches."Everything is Negotiable: Especially for cash-strapped startups, approaching regulatory and quality service providers with humility can lead to flexible contract structures that help build a strong foundation early.Clinical Data is for Post-Submission too: Don't just collect data to satisfy the FDA; identify "soft endpoints" that prove economic value to hospital value analysis committees and payers.Control Your Launch: A Limited Market Release (LMR) allows a startup to "get their nose bloodied" on a small scale, refining the sales methodology before attempting to scale nationally.Avoid the "Bottom of the Bag" Syndrome: Be cautious with large distribution agreements early on. If the sales force isn't properly incentivized or trained, your product may be ignored in favor of higher-margin legacy items.ReferencesMedTech Innovator: The world's largest accelerator for medical device companies.Hal Stowe (Eurofins): Referenced for his recent article on the strategic value of a purposeful regulatory strategy.Etienne Nichols: Connect with the host on LinkedIn.MedTech 101: The 510(k) vs. IDEIn this episode, John mentions having a 510(k) clearance but needing an IDE trial.510(k): Think of this as the "Me Too" pathway. You are telling the FDA your device is "substantially equivalent" to one already on the market. It gets you through the door, but often with limited claims (a "tool claim").IDE (Investigational Device Exemption): This allows your device to be used in a clinical study to collect safety and effectiveness data. It's like a "permit" to do the deep research needed to prove your device can treat a specific, high-stakes condition like a pulmonary embolism.SponsorsThis episode is brought to you by Greenlight Guru. For MedTech founders looking to avoid the regulatory headaches discussed today, Greenlight Guru offers the only dedicated Medical Device Success Platform. From their industry-leading QMS (Quality Management System) to their robust EDC (Electronic Data Capture) solutions, they help you move from concept to commercialization faster while staying compliant. Connect your quality data to your clinical trials to build the "ring fence" of value John Schindler discussed.Feedback Call-to-ActionWe want to hear from you. Did John's take on simplicity change how you view your product roadmap? Do you have a "Founder 101" topic you want us to cover? Send your thoughts, reviews, and suggestions to podcast@greenlight.guru. We read every email and pride ourselves on providing personalized responses to our MedTech community.

What happens when you apply the scaling laws of large language models to the physical work of atoms? Elad Gil sits down with Liam Fedus, co-founder at Periodic Labs, which is pioneering an AI foundation lab for atoms. Liam discusses how he pivoted from dark matter physics research to the front lines of artificial intelligence, including stints at Google Brain and working on ChatGPT at OpenAI. He talks about how Periodic is connecting massive language models to the physical world to overcome data bottlenecks in material science. Liam also shares how they use language models as an orchestration layer operating alongside specialized neural nets to run closed-loop physical experiments. They also explore the future of AGI and ASI, as well as the role of robotics in lab automation. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @LiamFedus | @periodiclabs Chapters: 00:00 – Cold Open 00:05 – Liam Fedus Introduction 00:39 – Liam's Background at Google Brain, OpenAI 05:14 – From ChatGPT to Materials and Atoms 06:34 – Training Data in the Physical World 09:52 – Generalization Across Domains 11:31 – Models as an Orchestration Layer 12:48 – Commercialization and Business Model 16:10 – How Periodic's Success May Shape the Future  17:45 – Multidisciplinary Scaling 19:41 – Capital and Compute 21:12 – Hiring at Periodic 21:44 – Thoughts on AGI and ASI 23:30 – Timeline for Machine-Directed Self-Improvement 25:39 – Automation and Data Generation 27:59 – Why Liam is Excited About the Future of Robotics 29:25 – Conclusion

Shaped by diverse markets, languages, currencies and regulatory frameworks, Europe presents a complex landscape for businesses operating across the region. Understanding that landscape is essential for companies managing treasury, liquidity and cross-border payments. In this episode of EMEA in Conversation, Stew Cofer, EMEA head of Payments Specialists, Commercialization and Embedded Finance and Alison Livesey, head of UK and Europe Subsidiary Banking, examine the forces shaping payments across Europe today. From evolving regulatory environments to the realities of operating across multiple markets, the discussion explores how businesses are managing financial flows, approaching treasury strategy and supporting cross-border commerce across the region.    ©2026 JPMorgan Chase & Co. All rights reserved. JPMorgan Chase Bank, N.A. Member FDIC. Deposits held in non-U.S. branches are not FDIC insured. Non-deposit products are not FDIC insured. All rights reserved. The statements herein are confidential and proprietary and not intended to be legally binding. Not all products and services are available in all geographical areas. Visit jpmorgan.com/paymentsdisclosure for further disclosures and disclaimers related to this content. This video-podcast/guide is confidential and proprietary to J.P. Morgan and is provided for your general information only. It is subject to change without notice and is not intended to be legally binding. Any services described in this video-podcast/guide are subject to applicable laws and regulations and service terms. Not all products and services are available in all locations. Eligibility for particular products and services will be determined by JPMorgan Chase Bank, N.A. or its affiliates. J.P. Morgan makes no representations as to the legal, regulatory, tax or accounting implications of the matters referred to herein. Any mentions of third-party trademarks, brand names, products and services are for referential purposes only and any mention thereof is not meant to imply any sponsorship, endorsement, or affiliation. J.P. Morgan and J.P. Morgan Payments are marketing names for certain businesses of JPMorgan Chase & Co. and its affiliates and subsidiaries worldwide JPMorgan Chase Bank, N.A., organized under the laws of U.S.A. with limited liability. The views and opinions expressed herein are those of the author and do not necessarily reflect the views of J.P. Morgan, its affiliates, or its employees. The information set forth herein has been obtained or derived from sources believed to be reliable. Neither the author nor J.P. Morgan makes any representations or warranties as to the information's accuracy or completeness. The information contained herein has been provided solely for informational purposes and does not constitute an offer, solicitation, advice or recommendation, to make any investment decisions or purchase any financial instruments and may not be construed as such.

We're doubling down on our YouTube content, so if you want to watch this video instead of listening to it, you can watch it on our channel here: https://www.youtube.com/@SuccessionBioSonya Weigle: https://www.linkedin.com/in/sonya-wilford-weigle/About Succession  Succession helps founders and sales teams close more deals with biotech and pharma. We partner with our clients to run modern lead generation campaigns, up-skill their team through personalized sales training, and build AI workflows using cutting-edge tools and technology.Ready to take your go-to-market to the next level?Check out all our free tools: https://succession.bio/free-tools  Subscribe to our newsletter: https://blog.succession.bioBook a strategy call:www.succession.bio  Ask us anything: https://forms.gle/6cJJo7imyekPcwdEA

In this episode, Rick Peng, Digital Ventures Lead in Memorial Sloan Kettering Cancer Center (MSK) Office of Entrepreneurship & Commercialization & Natalia Summerville, PhD, Director of Decision Intelligence at Memorial Sloan Kettering Cancer Center, discuss how MSK is advancing AI across clinical care and research while building a robust governance model. They share insights on balancing innovation with safety, ensuring accountability, and driving real impact through thoughtful AI deployment and monitoring.

In this episode, Rick Peng, Digital Ventures Lead in Memorial Sloan Kettering Cancer Center (MSK) Office of Entrepreneurship & Commercialization & Natalia Summerville, PhD, Director of Decision Intelligence at Memorial Sloan Kettering Cancer Center, discuss how MSK is advancing AI across clinical care and research while building a robust governance model. They share insights on balancing innovation with safety, ensuring accountability, and driving real impact through thoughtful AI deployment and monitoring.

Episode SummaryWhat does it actually take to sell tons of product … not as a metaphor, but by the truckload?In this episode of Product: Knowledge, Laurier Mandin shares real-world product marketing case studies where slow or stagnant sales turned into explosive growth. In one case, a barbecue product went from zero sales to 180 tons sold in just a few months.These examples reveal a consistent pattern: the products that win don't rely on claims—they prove their value in ways buyers can immediately understand.This episode breaks down how to create that kind of proof, why it works, and where even successful products can fail.What You'll LearnWhy “show, don't tell” is the most reliable marketing advantageHow demonstration beats high-production advertisingWhat skeptical buyers actually need to convertWhy proof-based marketing scales faster than persuasionThe hidden operational risk that can kill a winning productThe one capability AI cannot replace in product positioningKey Case StudiesA barbecue product scaled from zero to 180 tons soldA fishing lure that broke through a saturated category using visual proofBlendtec's “Will It Blend?” as a model for demonstration marketingA premium pillow that combined emotional and technical differentiationA guitar device that built credibility through expert validationCore InsightThe products that scale fastest remove interpretation.They don't explain why they're good.They make it obvious.Notable Quote“You can't read your own label from inside the bottle.”Chapters00:00 – Introduction: selling by the ton01:11 – SearBQ: zero to 180 tons02:04 – Why the original ad failed02:19 – The demonstration breakthrough03:02 – SmartFish: proof in a crowded market03:52 – Why proof converts04:00 – Blendtec and viral demonstration04:56 – When proof isn't enough05:01 – Parallel Pillow: skepticism as strategy06:04 – BzzzzKill: credibility and community06:49 – The failure behind success (economics)07:44 – What AI cannot do10:02 – The shared pattern behind winning productsLinks & ResourcesProduct marketing insights: https://graphosproduct.comDaily Need Feed emails and buy Laurier Mandin's book, “I Need That”: https://lmandin.com

In this episode, Vineet Gupta, PhD, FASN, Vice President of the Office of Innovation and Commercialization and CEO of Medical Branch Innovations at The University of Texas Medical Branch, discusses embedding innovation as a fourth pillar alongside clinical care, research, and education. He shares how strategic focus areas such as brain health, kidney health, healthy aging, and AI driven solutions are advancing commercialization, public private partnerships, and systemwide transformation.

On the show this week, our guest is Dinesh Narayanan, Head of Commercialization, General Robotics. Dinesh shares insights into the founding of General Robotics, highlighting the transition from Microsoft and the development of their proprietary platform, Grid. This platform aims to streamline the deployment and scaling of robotics solutions by integrating simulation, AI models, and deployment pipelines. Dinesh emphasizes the importance of adaptability in AI techniques and the company's focus on providing rapid prototyping and deployment capabilities. The conversation also touched on the potential of humanoid robots and the role of Grid in facilitating their development. Dinesh concludes by discussing the company's business model and future aspirations, drawing parallels to the impact of platforms like AWS and Azure in the tech industry. ### – SPONSOR – Download the 2026 State of the Robotics Industry Report: https://www.therobotreport.com/state-of-robotics-industry-report-2026/

Send a textKeywordsF1, Ferrari, Aston Martin, Cadillac, Red Bull, Mercedes, Alpine, Formula 1, 2026 season, driver dynamicsSummaryIn this episode, Adam and John dive into the latest developments in Formula 1 as they prepare for the 2026 season. They discuss Ferrari's innovative designs, Aston Martin's struggles, Cadillac's promising entry, and the dynamics within Red Bull and Mercedes. The conversation also touches on team strategies, driver performances, and the implications of new regulations. As they share their predictions for the upcoming races, they reflect on the significance of driver numbers and the legacy of champions in the sport.TakeawaysFerrari is making bold innovations but faces skepticism about their legality.Aston Martin is struggling significantly with technical issues and performance.Cadillac's entry into F1 is generating excitement among fans and analysts alike.Max Verstappen's dissatisfaction with the new car format raises questions about Red Bull's future.Mercedes is employing strategic advantages under the new regulations.Alpine's lack of notable performance in testing is concerning for their fans.The dynamics between teammates can significantly impact team performance and morale.The significance of driver numbers and the choice to take the number one plate is a topic of debate.The upcoming Australian Grand Prix is seen as a pivotal moment for many teams.The hosts express a mix of hope and skepticism about the season ahead. TitlesF1 Testing Insights: Ferrari, Aston Martin, and MoreThe Rise of Cadillac in Formula 1 sound bites"It's a dumpster fire. It is so bad.""I'm excited for Cadillac.""I want to see a back marker come up, man."Chapters00:00 Introduction and Excitement for F100:28 Ferrari's Innovations and Challenges05:34 Aston Martin's Struggles08:41 Cadillac's Promising Performance10:07 Driver Dynamics: Bottas and Perez11:32 Red Bull's Strategy and Max Verstappen's Future16:06 Rookie Insights: Lawson and Lindblad20:47 Mercedes' Technical Edge23:07 Conclusion and Future Predictions23:14 F1 Protests and Engine Innovations25:33 Livery Designs and Aesthetic Choices27:38 Alpine's Underwhelming Performance30:07 Commercialization in F131:55 Apple's Impact on F1 Coverage34:45 Comparing F1 and IMSA Racing Dynamics36:41 Predictions for the Upcoming Race39:20 The Significance of the Number One PlateSupport the show

In this episode of Investor Connect, Hall T. Martin welcomes Michelle Leeuwon, a leader in technology commercialization at the University of Houston working at the intersection of innovation, entrepreneurship, and ecosystem development. Michelle shares how UH treats commercialization as a translational process—"cultivating deals" by asking three key questions: what problem is solved, who feels the pain enough to pay, and what meaningful proof reduces risk. She explains how her team selects the right pathway (licensing vs. startup formation), aligns technology with market needs, and helps founders narrow use cases, set realistic development and funding timelines, and define clear team roles. The conversation also covers proof-of-concept (gap) funding to build prototypes, validate applications, support scale-up, and drive customer discovery, along with an IP strategy focused on protecting "relevant novelty" to enable licensable, investable deals. Michelle discusses early engagement with industry and investors for feedback, best practices for pairing inventors with experienced operators through UH's Innovate accelerator, metrics centered on risk reduction, and closes with her contact details for licensing and startup opportunities. Reach out to at wwan@central.uh.edu, and on www.linkedin.com/in/michelle-leeuwon-486624170/ ________________________________________________________________________ For more episodes from Investor Connect, please visit the site at: http://investorconnect.org Check out our other podcasts here: https://investorconnect.org/ For Investors check out: https://tencapital.group/investor-landing/ For Startups check out: https://tencapital.group/company-landing/ For eGuides check out: https:/_/tencapital.group/education/ For upcoming Events, check out https://tencapital.group/events/ For Feedback please contact info@tencapital.group Please follow, share, and leave a review. Music courtesy of Bensound.

When a development-stage technology company raises new capital while simplifying the governance structure of a key technology partner, it can signal a shift in how management plans to advance its programs. In this case, that transition is defined by HPQ Silicon closing a fully subscribed $3 million non-brokered private placement, while simultaneously finalizing its increased ownership and revised governance framework at Novacium SAS.HPQ Silicon, a Québec-based advanced materials and process development company, intends to use the capital to support general working capital, advance a matching $3 million NRCan-supported silicon-based battery materials program, and continue development of its hydrogen technologies, while the Novacium restructuring is designed to support access to targeted funding programs in France and Europe. Together, these developments provide the company with additional capital and a simplified governance structure as it continues advancing its technology platforms.$3M Financing Closed: HPQ raised $3M CAD byissuing approximately 18.18 million units.NRCan Program Advancement: Participation in the NRCan-supported silicon battery materials program requires HPQ to incur eligible costs before reimbursement.Novacium Governance Update: Ownership in Novacium increased to 36.8%, while HPQ converted its Category P priority share into common shares, simplifying governance.Energy transition technologies and advanced materials development often require significant capital and long development timelines. As electrification expands and demand grows for higher-performance batteries and alternative energy systems, companies are exploring new materials and delivery technologies designed to improve performance and reliability.Through Novacium, HPQ is advancing silicon-based anode materials. According to previously reported testing results released by the company, Novacium's GEN3 silicon-based anode batteries demonstrated more than 1,000 charge cycles and approximately a 30% cumulative energy gain compared with graphite-based benchmark batteries under reported testing conditions.Novacium is also advancing METAGENE, a hydrogen technology platform focused on enabling on-demand energy generation. During the interview, management stated it believes the company now has clearer visibility on potential commercialization pathways, including specialized battery applications, partner-financed fumed silica production facilities, and hydrogen deployments aligned with remote energy needs and critical-minerals development.The $3M financing, completed with an investor outside Canada, is intended to provide working capital and allow the company to continue advancing its development programs while pursuing potential partnerships, government support, and commercial opportunities.CEO BERNARD TOURILLON“We've reached the point where the fly-by-the-seat-of-your-pants structure just doesn't work anymore. We believe we know where our revenues are going to come from, and we needed to stop thinking quarter to quarter and fund the plan.”For investors, the interview outlines management's view that the financing and Novacium governance changes provide additional capital and structural clarity as HPQ advances its technology platforms.The private placement supports continued work on the NRCan-supported silicon-anode battery materials program, while also supporting hydrogen technology development and general corporate initiatives.At the same time, Novacium's simplified governance structure may help align the company with potential European energy and innovation funding programs, while HPQ's ownership position in Novacium increases to 36.8%.Management also indicated that fumed silica commercialization may be pursued through partner-financed plant structures, which could allow HPQ to focus its capital on battery materials and hydrogen technologies.

Host Jason Blitman sits down with author Amy Jo Burns — who returns to Gays Reading after co-interviewing Abraham Verghese with Jason in summer 2024 — to discuss her latest novel, Wait for Me, the March pick for Read with Jenna's book club.Conversation highlights include:

From Obamacare's limitations to the Bayh-Dole Act, Dr. Abramson reveals how commercial interests overtook public health priorities in research and care. #HealthcareReform #ProfitOverPatients #BayhDole

In this episode of Tank Talks, Matt Cohen sits down with Christian Weedbrook, founder and CEO of Xanadu, and Bill Fradin, CEO of Crane Harbor Acquisition Corp., to explore the historic SPAC merger that is bringing Xanadu to the public markets. With a focus on photonic quantum computing, Xanadu has rapidly advanced in the quantum tech space, positioning itself as a leader in both hardware and software innovation.The merger, which values Xanadu at $3 billion, will not only help accelerate the company's growth but also raise significant capital, enabling it to expand its groundbreaking quantum computing solutions. Christian and Bill dive into why they chose the SPAC route, the strategic value behind their merger, and what sets Xanadu apart in the competitive quantum ecosystem.In addition, the episode takes a deep dive into Xanadu's PennyLane software, which is already making waves in academia and the broader quantum community, and explores how the public market debut will position the company for future commercialization and innovation. Whether you're an investor looking to understand quantum tech's potential or someone interested in cutting-edge science, this episode is a must-listen.Introduction to Xanadu's Quantum Computing Vision (01:23)Christian Weedbrook gives a quick overview of Xanadu's mission to build useful quantum computers with their photonic modality using lidar photons. Learn how they're positioning themselves in both hardware and software through their PennyLane software stack.Xanadu's Decision to Go Public (04:09)Christian explains why going public was always part of Xanadu's strategy and how the company transitioned from private funding rounds to a SPAC merger, raising $275 million in just four weeks.Why Choose a SPAC (10:02)Christian and Bill discuss the advantages of a SPAC over traditional IPOs, particularly for deep-tech companies like Xanadu, where the usual metrics for IPOs aren't always applicable.The Power of PennyLane (14:43)Christian highlights the growing adoption of PennyLane, Xanadu's quantum software, which is already being used across 150 universities worldwide and growing. Learn how going public will further accelerate its adoption.Strategic Partnerships and the Path to Commercialization (16:20)Bill shares insights on how going public will help Xanadu expand its industry partnerships, including major players like Volkswagen and Rolls-Royce, and how these collaborations could lead to breakthroughs in areas like electric vehicle batteries and pharmaceuticals.Energy Efficiency and the Future of Quantum Computing (24:39)Christian explains how quantum computing can drastically reduce energy consumption in computing, using Xanadu's Borealis quantum computer as an example. This new approach promises significant energy savings, especially in industries like AI, drug discovery, and material design.Xanadu's Road Ahead in the Public Market (27:27)Christian reflects on the monumental journey Xanadu has been on, comparing it to the early days of the internet and digital computing. He also discusses how this milestone will change the company's trajectory and impact the quantum computing ecosystem.About Christian WeedbrookChristian Weedbrook is the founder and CEO of Xanadu, a leading quantum computing company based in Toronto. With a passion for quantum technology, Christian has spearheaded the development of Xanadu's groundbreaking photonic-based quantum computers. His leadership has positioned Xanadu as one of the pioneers in quantum computing, not only through its hardware advancements but also with the development of its PennyLane software platform. Christian's vision is to build quantum computers that are both useful and accessible to people around the world, and he is committed to driving forward the next era of quantum technology.Connect with Christian Weedbrook on LinkedIn: https://www.linkedin.com/in/christianweedbrook/Visit the Xanadu website: https://www.xanadu.ai/About Bill FradinBill Fradin is the CEO of Crane Harbor Acquisition Corp., a SPAC focused on identifying and merging with innovative companies in the tech sector. With over 20 years of experience in the financial industry, Bill has been at the forefront of numerous successful SPAC transactions, specializing in high-growth, disruptive technology companies. His leadership has been integral to bringing Crane Harbor to the public markets, and he has built a strong reputation for identifying companies with significant long-term potential. Bill's experience in both private and public markets has made him a trusted partner for visionary companies like Xanadu, helping them navigate the complexities of the SPAC process and positioning them for success in the public arena.Connect with Bill Fradin on LinkedIn: https://www.linkedin.com/in/bill-fradin-83196b3/Visit the Crane Harbor Acquisition Corp website: https://www.craneharboracquisition.com/Connect with Matt Cohen on LinkedIn: https://ca.linkedin.com/in/matt-cohen1Visit the Ripple Ventures website: https://www.rippleventures.com/ This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit tanktalks.substack.com

“Practicing yoga is not really something separate from me. It is happening all the time.” In this episode of a Curious Yogi Podcast, yoga teacher Myra Khanna shares her journey from Kathak dancer and scuba diving instructor to dedicated yoga practitioner and teacher. Drawing from studies with Bharath Shetty, Vinay Kumar, Vijay Kumar, Deepika Mehta, Mark Robberds, Eddie Stern, and ongoing training with Yoga Education College, Myra reflects on her evolution from a physically driven Ashtanga practice to a more holistic exploration of pranayama, meditation, and nervous system regulation.The conversation explores the commercialization of yoga, misconceptions about yoga in India, female health awareness in asana practice, and the parallels between diving and meditative practice. Myra also shares how traditional strength disciplines like mudgar swinging, dandas, and baithaks inform her approach to resilience and sustainability in practice.Here are some key takeaways; ➖ Transition from purely physical to a more holistic practice.➖ Emphasize the importance of listening to one's body and nervous system.➖ Commercialization of yoga impacts its true essence.➖ Teaching should accommodate students' individual needs and journeys.➖ Diving parallels the meditative aspects of yoga.➖ Myra's passion for education on female health in yoga after becoming unwell. Connect with Myra: IG @myrakhann02 I really enjoyed this conversation as an invitation to reconsider yoga as a living, evolving process — one rooted in curiosity, community, and embodied awareness. I know you will also dear listeners. In oneness, Bobbi Thanks for listening!

In this episode of The Syneos Health Podcast, Conversations on Commercialization, Tyler Cowan, VP, Commercial speaks with Paul Rittman, President and General Manager of Almirall US, about how payer consolidation and PBM influence are reshaping dermatology commercialization.   They discuss how pharmaceutical companies must adapt launch strategy, market access planning and clinical differentiation to succeed in today's competitive specialty landscape. The conversation explores the growing role of digital engagement, direct-to-consumer (DTC) strategy, telehealth and cash-pay models in improving patient access.   Listeners will gain practical insights into how innovation, payer strategy and patient-centric commercialization drive success in dermatology and specialty pharma.  The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Join us in this episode where we explore the latest in football controversies, psychological insights into players' behavior, and pressing societal issues like racism in sports. With lively debates, vibrant opinions, and detailed timestamps, this episode offers both entertainment and critical reflection.Arsenal's pursuit of quadruple amidst a competitive leagueRacism and racial abuse in European football, especially Vinicius Jr.'s incidentThe impact of club owners and managerial comments on societal perceptionsPlayer behavior, celebration etiquette, and on-field tensionsWorld Cup ticket pricing controversies and commercialization of footballCommentary on players' mental health, growth, and performance statistics00:00 - Introduction & Arsenal's season updates—top of the league and potential quadruple chase 01:13 - Manchester United's league standing and banter with rivals 02:47 - Valentine's Day celebrations and personal life updates 03:42 - Discussion on club holidays and work-life balance 04:45 - Addressing Valentine's plans and singlehood 05:36 - Support for clubs and fans' emotional investments 08:11 - Critical analysis of Manchester United's owner's comments on immigrants 09:42 - Racism in football: Vinicius Jr.'s racial abuse in Spain 13:26 - Champions League match between Benfica and Real Madrid—celebration and booing incident 15:33 - Incident of racial slurs during the game and Mourinho's comments 17:38 - Profound disappointment in Mourinho's stance; referee's role and on-field abuse 19:28 - Broader societal implications of racism and athlete responses 23:00 - Referee decisions and yellow card controversies in the game 25:20 - Stand with Vinicius Jr. and addressing racial abuse on and off the pitch 29:58 - In-depth debate on the interpretation of racial slurs, lip-reading, and bias 35:10 - Video evidence, reactions, and the importance of context in abuse accusations 36:44 - Player emotions, reactions, and the dynamics of team behavior during abuse incidents 41:07 - The importance of investigations and avoiding accusations without proof 44:26 - Commercialization of football: Players' roles versus corporate interests 45:14 - Societal perceptions of players' opinions outside football 48:40 - FA Cup updates, Chelsea, and Arsenal fixtures 55:05 - Player development, growth spurts, and stats analysis 61:44 - Promoting supportive community channels and personal endeavors 63:13 - Upcoming matches, league standings, and closing remarks

In this Mission Matters episode, Adam Torres interviews Kevin McGovern, Chairman of McGovern Capital LLC, about his journey from investing in the stock market in seventh grade to building global brands like SoBe and mentoring the next generation of entrepreneurs through purpose-driven investing. About Kevin McGovern Kevin McGovern is Chairman and CEO of McGovern Capital, a New York–based single-family office that invests globally in innovative companies and strategic opportunities. Through McGovern Capital and its affiliates, he has co-founded over 25 companies, six of which became world or category leaders, and has served as lead negotiator in more than 15 international joint ventures across approximately 80 countries. McGovern was a founder of SoBe Beverages, helped popularize advanced water filtration technologies, and licensed skincare innovations used in ~40 % of products worldwide. He also serves on public and private boards, speaks internationally at academic and family office events, and has taught “Global Innovation and Commercialization” at top universities including Cornell, Stanford, MIT, and Harvard. About McGovern Capital LLC McGovern Capital LLC is a leading private investment firm and intellectual property strategist based in New York City, Greenwich, CT, and Miami, Florida. The firm originates, funds, structures, and implements capital formation as well as domestic and international joint ventures and business alliances, and provides early-stage capital and facilitative services to its portfolio companies. Through its global network, McGovern Capital and its affiliates have co-founded over 25 companies, including six category leaders such as SoBe Beverages and KX Industries, and have conducted business in approximately 80 countries. The firm specializes in go-to-market strategies for disruptive technologies and consumer-focused innovations, helping founders assess, strategize, and monetize intellectual property and business opportunities worldwide. Watch Full Episode On Youtube --- Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices Learn more about your ad choices. Visit podcastchoices.com/adchoices

PREVIEW FOR LATER TODAY Guest: Bob Zimmerman. Zimmerman details Starfish's $154 million Pentagoncontract using space tugs to service and de-orbit satellites, highlighting the growing commercialization of low Earthorbit.1957

Atombeam CEO Charles Yeomans joins Chris Lustrino to break down a deceptively simple idea with massive implications: make data smaller while it's streaming so you can move and process more of it—without upgrading networks.Charles explains Atombeam's commercial product NeurPack, how it can often quadruple effective bandwidth, and why this matters across IoT, smart meters, satellites, defense, oil & gas wells, fintech, and eventually data centers and GPU utilization. They also dig into the realities of commercialization—choosing near-term deals that close fast while still pursuing multi-year “industry standard” opportunities—and why execution (not invention) is the real differentiator.00:00 What Atombeam does (pizza analogy)03:13 NeurPack explained05:35 Why 95% of IoT data doesn't move09:38 “Like launching 3 more satellites”13:57 Commercialization + customers16:31 Data centers + GPU utilization24:29 Defense traction + partnerships26:44 What success looks like (distribution)

NASA technology brings the golden age of exploration to Earth.

Neurologist Dr. Vinit Banga explains stress, sleep, stroke symptoms, brain health, and the effects of pollution on the brain in this powerful podcast episode with Gaurav Arora.This episode covers:•Stress symptoms and how chronic stress damages the brain•Deep sleep and why sleep is essential for brain repair•Stroke warning signs (FAST symptoms) and why minutes matter•Brain fog, memory loss, cognitive decline, early dementia signs•Delhi pollution / AQI effects on brain ageing and intelligence•Migraine triggers, headaches, and dangerous neurological red flags•Doctor-patient trust, Practo ratings, healthcare commercialization in India00:00 Impact of Delhi's Pollution on Brain Health00:37 Stress and Its Effects on Health01:39 Air Quality and Brain Aging03:24 Blood-Brain Barrier and Pollution06:03 Memory Issues and Aging07:04 Understanding Memory Formation12:20 Sleep Disorders and Brain Health13:35 The Importance of Deep Sleep16:09 Stress: The Silent Disruptor46:38 Doctor-Patient Trust and Ethical Concerns55:14 Commercialization in Healthcare01:04:15 Concluding Thoughts and GratitudeDr. Vinit Banga is Director & Head of Neurology & Neurovascular Intervention at Fortis Escorts, and shares life-saving insights on preventing stroke, protecting brain function, and understanding modern neurological risk factors.Keywords: neurologist podcast, brain health India, stress and stroke, sleep and brain, stroke symptoms, stroke warning signs, Delhi pollution brain damage, brain fog, dementia signs, migraine, Fortis neurologist, Dr Vinit Banga, Gaurav Arora podcast.#Stress #Stroke #BrainHealth #Sleep #Neurology #Podcast #DrVinitBanga

Episode 60: Revolutionizing and Democratizing Autonomous Driving  Alex Kendall, founder and CEO of Wayve, a UK-based company with $1.3 billion of funding from Microsoft, NVIDIA, Softbank and Uber, discusses Wayve’s head start in end-to-end AI for driving, its efficient training and run-time architecture, and its suitability to any car manufacturer.  00:00 Welcome to Tech Cars Machines  01:32 Introduction to Alex Kendall and Wayve  02:00 Wayve’s Autonomous Technology Explained  04:21 The End-to-End AI Approach  06:54 Wayve’s Data Efficiency and Learning  09:13 Alex Kendall’s Background and Journey  12:07 Wayve’s Path to Commercialization  23:22 Wayve’s Competitive Edge and Market Position  25:41 Adoption and Consumer Perception of Autonomous Vehicles  31:56 Customization and OEM Integration  35:51 Future of Autonomous Driving and Industry Impact 

Hello, hello! In this episode of the Good Garbage Podcast, host Ved Krishna sits down with Neha Jain, Founder & CEO of Zerocircle, to explore how seaweed-based materials could transform the future of sustainable packaging. Imagine a world where packaging doesn't end up stranded on beaches, but instead safely dissolves back into nature. That's the future Neha is working toward.Neha shares her journey from working at Google to building Zerocirlce, a company focused on developing natural polymer materials from seaweed as an alternative to plastic packaging. This conversation dives deep into material science, the challenges of scaling sustainable packaging solutions, and why true sustainability must work commercially, not just environmentally.Together, Ved and Neha discuss:- How seaweed is used to create home-compostable packaging materials- The science behind natural polymers and plastic alternatives- Why collaboration is critical in the sustainable materials ecosystem- What it takes to scale climate-positive solutions globally- Why “good garbage” means designing systems where waste doesn't existZerocircle's vision goes beyond packaging aiming to become a core material provider for manufacturers worldwide, helping reduce plastic waste at scale. → Find out more about Zerocirlce: https://www.zerocircle.in/

Disease accelerates years in a month. Cancer cells reveal which patients might be most impacted by metastasis - a diagnosis invisible on Earth. Single crystals heal themselves through mechanisms we can't explain. These aren't projections. They're validated results from 2022-2025 that made 40-year NASA veterans say they'd never seen anything like it.The economics flipped. Merck flew Keytruda 30 days, discovered a crystal form missed in a decade of labs - $20B/year by 2030, exceeding SpaceX's entire revenue. The thesis: Two paths to space affordability: cut launch costs 10x AND multiply payload value 1,000x. Do what Earth cannot do at any price.Paradigm Shifts:

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Wei-Wu, Executive Chairman at Human Longevity, Inc. Together, they explore how advances in genome sequencing, AI, and multi-layered diagnostics are changing the fight against age-related diseases. Wei-Wu shares why understanding your own genetic risks and combining them with other health data leads to better prevention and a longer healthspan.Wei-Wu explains the value of integrating genome sequencing, advanced imaging, and liquid biopsy to catch diseases like cancer early, before symptoms appear. He draws on real-world examples, including how combining different tests can spot cancers that single methods might miss. The conversation highlights how technology brings down costs, making once-rare insights widely available, and how each person stands to benefit from personalized risk profiles.The episode closes with practical advice: use today's tools to become the CEO of your own health. Wei-Wu urges listeners to embrace data-driven, individualized care and stresses that no single tool or habit holds all the answers. Instead, true longevity comes from a holistic, ongoing approach, one that uses all available knowledge to prevent disease and extend both life and health.Guest-at-a-Glance

THE BLIP AND THE FUTURE Colleague Keach Hagey, The Optimist. The viral success of ChatGPT shifted OpenAI's focus from safety to commercialization, despite early internal warnings about the existential risks of AGI. Tensions over safety and Altman's management style led to a "blip" where the nonprofit board fired him, only for him to be quickly reinstated due to employee loyalty. Elon Musk, having lost a power struggle for control of the organization, severed ties, leaving Altman to lead the race toward AGI. NUMBER 16 FEBRUARY 1955

Why Dec. 25? Why so much Christmas conflict & controversy in Christianity's history? Why is Christmas so important to Christianity? And to America? In this episode, I ask my guest, Dr. Carey Roberts, the following questions: ►Why is Christmas such a grand celebration? What does this tell us about Christianity? ►Did it take a while for Christmas to take a central role in Christianity►What's the difference between recognition and celebration of Christmas►Did Christmas piggyback on existing Roman pagan traditions? ►How did Christmas enter America's culture? If not the Puritans, then which immigrant group introduced Christmas to America? ►Were there any regional differences in the celebration of Christmas?►When did U.S. businesses begin to capitalize on Christmas? ►Would President Grant have witnessed a similar Christmas celebration in Boston and Savannah? ►Would George Washington recognize our Christmas? How about Andrew Jackson? Abraham Lincoln? Teddy Roosevelt? ►What happened to Christmas after WWII? ►Is it a bad thing that non-Christians and/or non-practicing Christians celebrate Christmas? ⁠